Otitis externa (OE) is a common, debilitating condition affecting up to 1 in 5 dogs in their lifetime and is seen on a daily basis in first opinion practice.1,2
Otitis is always painful and usually pruritic and has been shown to affect both the quality of life of owners and their dogs who develop it.3 Whilst the development of otitis externa is not an emergency, it is a potentially urgent problem that could lead to significant welfare compromise if left untreated - https://www.bsava.com/TriageTool.
Otitis has been shown to have an impact on dogs’ sleep and playing behaviours, and cause their owners physical or emotional disturbances.3 Where otitis is not addressed adequately, a dramatic deterioration of the dog-owner relationship has been shown to occur, leading to low treatment compliance and the development of ear phobias in affected dogs.4 The key to therapy should be early intervention and based on recent quality of life studies, this should be with a veterinary directed treatment rather than an owner directed treatment.5
Neptra® is a one dose solution licensed for the treatment of the most common pathogens seen in 70-80% of OE cases (Staphylococcus pseudintermedius and Malassezia pachydermatis).
It contains a first line antibiotic (florfenicol) which is not on the WHO list of critically important antibiotics, improving antibiotic stewardship, as well as an antifungal (terbinafine) and a potent corticosteroid (mometasone furoate). This highly potent, but “soft” corticosteroid acts rapidly and effectively at a local level to reduce inflammation within the ear canal, with minimal systemic absorption. Neptra improves comfort and there is no need for owners to treat their dog at home – reducing stress for everyone and improving compliance.
Dr Sue Paterson MA VetMB DVD DipECVD FRCVS, RCVS and European Specialist in Veterinary Dermatology
Login or Register to MyElanco and answer the questions for a chance to win a £250 Amazon voucher!
Registered user? Click the competition link, login and you will be taken to the quiz.
New to MyElanco? Click the competition link and register. It will take a couple of minutes to sign up. Then click on the competition banner on your homepage.
The competition is open to vets and nurses over the age of 18 in the UK. See full details of the Terms and Conditions. The winner will be notified by an email shortly after the competition has closed, so be sure to keep an eye on your inbox, best of luck!
Neptra is an effective new option for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis).
The ONLY first-line treatment available in ONE vet-administered dose.
Offering complete control over compliance in the treatment of otitis externa, Neptra removes the owner responsibility, stress and uncertainty of repeated at-home treatments.
Ideal for first-line use and effective against the most common pathogens* - associated with 70-80% of OE cases, make Neptra your first choice for OE treatment.
Neptra contains a unique combination of three active ingredients that work together to be effective against the most common pathogens associated with otitis externa, as well as providing potent anti-inflammatory and anti-pruritic action, giving welcome relief from the discomfort of OE.
Provides powerful anti-inflammatory activity
An established first-line antibiotic, provides potent antibacterial activity
Provides potent anti-yeast activity
Neptra is the ONLY first-line treatment available in ONE vet-administered dose for canine otitis externa.
Its innovative formulation provides lasting action after one application, making the treatment of otitis externa easier for everyone.
with Dr Kenneth W. Kwochka, DVM, DACVD, President of the World Association of Dermatology
Dr Kenneth Kwochka discusses why Neptra is an ideal first line product for the majority of otitis externa cases which present with Staphylococcus pseudintermedius and Malassezia pachydermatis.
* Staphylococcus pseudintermedius and Malassezia pachydermatis.
Neptra POM-V (UK) and POM (Ireland) contains 16.7 mg florfenicol, 16.7 mg terbinafine hydrochloride, equivalent to terbinafine base: 14.9 mg, and 2.2 mg mometasone furoate.
Further information is available from the SPC. Advice should be sought from the Medicine Prescriber. Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contra-indications. Contact Elanco Animal Health for further information on 01256 353131 or email firstname.lastname@example.org, or write to: Elanco Animal Health, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA.
Neptra, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
© 2020 Elanco or its affiliates. PM-UK-20-0693. Date of preparation: 08/20.Use medicines responsibly www.noah.co.uk/responsible, www.apha.ie.